Completed PHASE4 INTERVENTIONAL 2-arm
NCT00117611
Xolair in Patients With Chronic Sinusitis
Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test
Sponsor: Genentech, Inc.
Conditions
Sinusitis
Interventions
Anti-IgE antibody omalizumab or placebo
Last updated: Sep 27, 2013 Started: Jul 31, 2005 Primary completion: May 31, 2007 Completion: Jan 31, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT00117611, this PHASE4 trial focuses on Sinusitis and remains completed. Sponsored by Genentech, Inc., it has been updated 0 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
No change history available.
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Genentech, Inc.
- Novartis Pharmaceuticals
- University of Chicago
Data source: University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .